Metaproterenol Other names: Orciprenaline

Inhalation of halogenated hydrocarbon anaesthetics such as halothane, trichloroethylene and enflurane may increase the susceptibility to the cardiovascular effects of beta-agonists.

Extreme care must also be exercised in the concomitant use of orciprenaline sulphate with epinephrine, monoamine oxidase inhibitors or tricyclic antidepressants since the action of beta adrenergic agonists may be enhanced.

Care should be taken in patients suffering from myocardial insufficiency, cardiac arrhythmias, recent myocardial infarction, severe organic heart and/or other vascular disorders, hypertension, hyperthyroidism, phaeochromocytoma or diabetes mellitus.

There is no well documented experience in pregnant women. Orciprenaline sulphate should only be used during pregnancy if the potential benefit outweighs the potential risk to the fetus.

It is not known whether orciprenaline sulphate is excreted in human milk; therefore, orciprenaline sulphate should be used during nursing only if the potential benefit justifies the possible risk to the newborn.